Novavax | NVAX - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Adma Biologics USD 61.59M 14.07M 2025-12
Agenus USD -10.61M 263.52M 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Cassava Sciences USD -10.81M 33.41M 2025-09
Geron USD -3.64M 27.5M 2026-03
GlaxoSmithKline GBP 2.14B 919M 2026-03
MannKind USD -16.37M 4.56M 2026-03
Merck USD 3.42B 3.32B 2025-12
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Moderna USD -799M 612M 2025-12
Novartis USD 5.17B 637M 2025-09
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Sanofi EUR -1.16B 5.5B 2025-12
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
TG Therapeutics USD 20.36M 24.73M 2026-03